 No significant differences (p > 0.05) were noted between the FPV/r100 and ATV/r100 regimens at week 48 (Figure 1) regarding proportion of patients achieving HIV-1 RNA < 50 copies/mL in the ITT: MD = F analysis (75% vs 83%) or ITT:observed analysis (89% vs 92%), nor in the proportion achieving < 400 copies/mL in these analyses (79% vs 87%); 93% vs 96%)
Once-daily (QD) ritonavir 100 mg-boosted fosamprenavir 1400 mg (FPV/r100)
atazanavir 300 mg (ATV/r100), plus tenofovir/emtricitabine (TDF/FTC) 300 mg/200 mg
Fasting total/LDL/HDL-cholesterol